Heartbeam宣布，作为公司重组计划的一部分，首席执行官罗伯特·伊诺将转任顾问职位。此次重组将涉及授权其用于心脏病发作检测的心电图信号技术。
这家医疗技术公司表示，重组将由公司总裁布拉尼斯拉夫·瓦伊迪奇和董事会主席里奇·法拉利领导。瓦伊迪奇指出，除了扩展其心电图技术外，公司将继续专注于先前宣布的临床研究，以加速其心脏病发作检测平台的开发。
Heartbeam表示，人工智能加速了其心电图平台的开发，而新战略的一个核心重点是将平台的应用范围从心律失常评估扩展到可靠的心脏病发作检测。公司补充称，其目标是通过与各国政府、卫生系统及各类型制造商建立合作伙伴关系，实现该技术的全球普及。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.